BEGIN:VCALENDAR VERSION:2.0 PRODID:-//chikkutakku.com//RDFCal 1.0//EN X-WR-CALDESC:GoogleカレンダーやiCalendar形式情報を共有シェ アしましょう。近所のイベントから全国のイベントま で今日のイベント検索やスケジュールを決めるならち っくたっく X-WR-CALNAME:ちっくたっく X-WR-TIMEZONE:UTC BEGIN:VEVENT SUMMARY:CBE Seminar: Matthew Helgeson\, University of California\, Santa B arbara\, “TBD" DTSTART;VALUE=DATE-TIME:20260929T153000Z DTEND;VALUE=DATE-TIME:20260929T163000Z UID:214215511480 DESCRIPTION:Sponsored by the Department of Chemical and Biomolecular Engin eeringHost: Alec Linotalinot@umass.edu413-545-6986 Matthew HelgesonUniver sity of California\, Santa Barbara“TBD” Tuesday\, September 29\, 2026 \, 11:30 a.m.201 LGRT\, UMass Amherst(Refreshments at 11:15 a.m.) Abstrac t:TBD Bio:TBD LOCATION:LGRT 201 END:VEVENT BEGIN:VEVENT SUMMARY:PhD Defense\, Shradha Khanduja\, “Engineering next-generation ba cterial therapies for the treatment of solid tumors” DTSTART;VALUE=DATE-TIME:20261001T150000Z DTEND;VALUE=DATE-TIME:20261001T163000Z UID:105073802610 DESCRIPTION:Committee Chair:  Neil ForbesABSTRACTMany biologic cancer the rapies do not effectively target tumors. When drugs are injected systemica lly\, they are quickly cleared from blood or are sequestered to other orga ns\, reducing the load in tumors and causing systemic toxicity. There curr ently exists no vehicle that can deliver any macromolecular therapy (DNA\, RNA\, or protein) selectively within tumors in a biomarker-independent ma nner. Here\, we present three critical classes of cancer therapies (DNA\, protein\, and cytokine therapies) that have shown limited success in the c linic due to ineffective tumor targeting and systemic toxicity. We then sh ow how Salmonella was engineered to focus delivery of each of these therap eutic classes selectively into tumors and reduce disease burden without co mpromising safety. Engineered Salmonella is tumor-tropic and safe and grow s exponentially in tumors independently of any tumor receptor.To demonstra te DNA delivery\, we chose to deliver oncolytic parvoviruses (MVMp and H-1 PV) into cancer cells. Oncolytic viruses (OVs) regress tumors by lysing ca ncer cells and inducing antitumor immune responses that can clear hard-to- treat and late-stage cancers. However\, when injected into the blood\, OVs are cleared or sequestered before reaching tumors. Because the parvovirus plasmid is not stable in Salmonella\, we deleted four homologous recombin ation genes (recB\, sbcB\, sbcCD and recF) from the Salmonella genome. Wit hout these deletions\, we discovered that Salmonella cannot induce viral e xpression and replication. To create Virus delivering Salmonella (VDS)\, t he engineered Salmonella was transformed with the parvovirus plasmid and a plasmid containing the intracellular delivery system (PsseJ-lysE). In cul ture\, VDS delivered virus to multiple cancers\, including breast\, pancre atic\, liver\, and osteosarcoma. In mice\, VDS delivered functional virus to mice with Hepa1-6 hepatomas\, and these viral particles reduced tumor v olume and increased survival compared to bacterial and viral-only controls . The delivery also generated anticancer immunity and suppressed tumor rec urrence.For protein delivery\, we chose to deliver Pseudomonas Exotoxin A (PEA) into pancreatic cancer cells. Therapeutic forms of PEA when injected systemically are highly immunogenic\, cause lymphopenia and have non-spec ific cytotoxicity. We stripped the receptor binding domain from PEA and de livered just the catalytic domain in the cytosol with engineered Salmonell a to solve this problem. The delivery resulted in tumor reduction in both nude and syngeneic mouse models of pancreatic cancer and activated anti-tu mor immune response in the syngeneic model.By minimally modifying the Salm onella\, we transformed the strain from an intracellular into an extracell ular delivery vehicle of IFNγ. IFNγ\, when delivered systemically causes severe adverse effects due to non-specific targeting. Moreover\, IFNγ ha s a short half-life in serum\, limiting tumor accumulation. We engineered the bacteria to lyse and release IFNγ extracellularly in the tumor microe nvironment. This delivery resulted in reduction in tumor volume in pancrea tic cancer and increased overall survival.By engineering Salmonella\, we c an deliver any therapy inside or outside the cell\, making this an attract ive tool for delivering drugs to solid tumors. LOCATION:N410\, Life Science Laboratories END:VEVENT BEGIN:VEVENT SUMMARY:CBE Seminar: Abdoulaye (Abdul) Djire\, Texas A&M University\, “T BD" DTSTART;VALUE=DATE-TIME:20261006T153000Z DTEND;VALUE=DATE-TIME:20261006T163000Z UID:307146214765 DESCRIPTION:Sponsored by the Department of Chemical and Biomolecular Engin eeringHost: Alexandra Zagalskayaazagalskaya@umass.edu413-545-7114 Abdoula ye(Abdul) DjireTexasA&\;M University“TBD”Tuesday\, October 6\, 2026 \, 11:30 a.m.201 LGRT\, UMass Amherst(Refreshments at 11:15 a.m.) Abstrac t:TBD Bio:TBD LOCATION:LGRT 201 END:VEVENT BEGIN:VEVENT SUMMARY:Indigenous People's Day - no classes DTSTART;VALUE=DATE:20261012 DTEND;VALUE=DATE:20261013 UID:329899578241 DESCRIPTION:Indigenous People's Day - no classes LOCATION: END:VEVENT BEGIN:VEVENT SUMMARY:CBE Seminar: Kannan Rangaramanujam\, Wayne State University\, “D evelopment and translation of cell-targeted systemic dendrimer precision n anomedicines" DTSTART;VALUE=DATE-TIME:20261013T153000Z DTEND;VALUE=DATE-TIME:20261013T163000Z UID:115556342780 DESCRIPTION:Sponsored by the Department of Chemical and Biomolecular Engin eeringHost: Ashish Kulkarniaakulkarni@umass.edu413-545-6892Kannan Rangaram anujamArnall Patz Distinguished Professor of Ophthalmology\, Center for Na nomedicine\, Johns Hopkins School of Medicine\, Baltimore\, Maryland\, USA  “Development and translation of cell-targeted systemic dendrimer preci sion nanomedicines”Tuesday\, October 13\, 2026\, 11:30 a.m.201 LGRT\, UM ass Amherst(Refreshments at 11:15 a.m.) Abstract:Dendrimers offer unique nanoscale attributes (e.g.\, surface group density) that can ‘tune’ th eir interactions with disease tissue and cells. Taking advantage of this\, we have developed dendrimers that target reactive microglia/macrophages\, injured’ neuronal cells\, adipocytes and more\, from systemic administr ation\, without a need for targeting ligands or antibodies. Through extens ive collaboration with physicians\, this has been validated in more than 5 5 animal models in six species\, and human tissue. Building on such select ive ‘disease biophysics’ uptake\, we have designed dendrimer-drug conj ugates which have shown significant promise in clinical trials\, addressin g decades-old medical challenges\, including overcoming the blood-brain ba rrier and developing systemic treatments for retinal disorders. These resu lts not only provide unique insights into the role of these key cells in d isease and repair but also offer opportunities for developing potent thera pies for unmet needs. Recent efforts to develop new applications in intrac ellular antibody delivery\, gene therapy\, and longevity will also be high lighted. Significant\, positive outcomes have been seen in six Phase 1 and two Phase 2 trials. OP-101@ (dendrimer-NAC conjugate) showed significant promise in Phase 2 trials for severe COVID-19 (>\;82% survival compared to 40% for standard of care) and was the only drug to address the neurolog ical consequences of COVID-19. Migaldendranib@ (dendrimer-sunitinib analog conjugate)\, a subcutaneous\, once-a-month\, cell-targeted therapy showed remarkable results in wet age-related macular degeneration and diabetic r etinopathy in Phase 2 trials (80% reduction in intravitreal Eylea@ injecti ons in BOTH eyes)\, with deep implications for early treatments for these large indications. The science of this biophysics-based cell-targeting\, a nd the remarkable promise of this approach in inflammatory\, brain\, pain\ , obesity\, mental health\, and retinal disorders will be discussed. Our a pproach suggests that novel solutions for long-standing problems may be at the exact opposite direction of conventional wisdom! Bio:Dr. Kannan Rang aramanujam is the Arnall Patz distinguished professor of ophthalmology and co-director of center for nanomedicine at the Wilmer Eye Institute at Joh ns Hopkins School of Medicine. He is a chemical engineer by training [PhD (Caltech)\; BE(Hons.) (BITS\, Pilani)]. His research interests are in the field of translational nanomedicine centered on novel approaches to target specific cells at the site of injury. His team has developed and extensiv ely validated the hydroxyl dendrimer and glucose dendrimer platforms throu gh Hopkins-wide collaborations in many animal models of ocular\, brain dis orders\, pain\, depression\, and cancer. These have the opportunity to add ress long-standing challenges in the field and will lead to medicines that are easy to administer (e.g.\, oral pills for AMD and diabetic retinopath y)\, have minimal side effects\, and affordable to large fractions of the world population. He is leading the translation of his research to the cli nic\, through start-ups and partnerships.  He is the co-founder of Ashvat tha Therapeutics Inc. and Samata Therapeutics (>\;$120M raised)\, and Av atar Precision Therapeutics – Johns Hopkins spinoffs that are translatin g some of his team’s patented dendrimer technologies to the clinic\, wit h three products that have completed Phase 2 trials. Dr. Rangaramanujam is an author of >\;190 patents (issued and pending\, licensed)\, >\;170 peer-reviewed publications\, and is supported by significant NIH and feder al funding. He has won several recognitions\, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE)\, IAMBE\, C ontrolled Release Society\, and Distinguished Alumni Award from BITS (Pila ni). He is on the editorial boards of Biomaterials\, Advanced Drug Deliver y Reviews\, and Theranostics. https://gritdaily.com/dr-kannan-rangaramanuj am-translational-nanomedicine/ LOCATION:LGRT 201 END:VEVENT BEGIN:VEVENT SUMMARY:CBE Graduate Program Virtual Information Session DTSTART;VALUE=DATE-TIME:20261016T140000Z DTEND;VALUE=DATE-TIME:20261016T153000Z UID:236038059858 DESCRIPTION:CBE Graduate Program Virtual Information Session LOCATION:Virtual END:VEVENT BEGIN:VEVENT SUMMARY:11:30 Faculty Meeting DTSTART;VALUE=DATE:20261022 DTEND;VALUE=DATE:20261023 UID:194519533987 DESCRIPTION:\nHere's the zoom link:\n\nTopic: CBE Faculty Meetings\nTime : This is a recurring meeting Meet anytime\nJoin Zoom Meeting\nhttps:// umass-amherst.zoom.us/j/97994627767\n\nMeeting ID: 979 9462 7767\nPasscode : 01003 LOCATION:153 Goessmann END:VEVENT BEGIN:VEVENT SUMMARY:UMass Amherst Engineering and Computing Career Day for High School Students DTSTART;VALUE=DATE:20261026 DTEND;VALUE=DATE:20261027 UID:168731443906 DESCRIPTION:Keynote Speaker: Dr. Karin Rotem-Wildeman\, Keurig Dr. Pepper LOCATION: END:VEVENT BEGIN:VEVENT SUMMARY:Tang Lecture - Karin Rotem - TBD DTSTART;VALUE=DATE-TIME:20261027T200000Z DTEND;VALUE=DATE-TIME:20261027T210000Z UID:295783060483 DESCRIPTION:Tang Lecture - Karin Rotem - TBD LOCATION: END:VEVENT END:VCALENDAR